Update on the use of imatinib mesylate

Clinical Advances in Hematology and Oncology

Volumn 3, Issue 10, 2005, Pages 757-758

  Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; STEM CELL FACTOR; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

CANCER CHEMOTHERAPY; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG USE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; LONG TERM CARE; NOTE; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES;

EID: 28944446972     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (7)

1. Chen LL, Sabripour M, Andtbacka RH, et al. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep. 2005;7:239-299.
2. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. 2003;17:2998-3010.
3. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
4. Anghel G, De Rosa L, Ruscio C, et al. Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement. Tumori. 2005;91:67-70.
5. O'Hare T, Walters DK, Stoffergen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;56:4500-4505.
6. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (ST1571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117-125.
7. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401.